Fund Evaluator:
Eventide Healthcare & Life Sciences N (ETNHX)
Follow This Fund
Best Performing in Health Over the Last Year
| 77.3% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 77.1% | Fidelity Advisor Biotechnology I (FBTIX) |
| 71.4% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 71.0% | Fidelity Select Biotechnology (FBIOX) |
| 58.4% | Rydex Biotechnology Inv (RYOIX) |
Fund Details
Eventide Healthcare & Life Sciences N Overview
Eventide Healthcare & Life Sciences N (ETNHX) is an actively managed Sector Equity Health fund. Eventide Funds launched the fund in 2012.
The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.
About Eventide Healthcare & Life Sciences N (ETNHX)
There are 2 members of the management team with an average tenure of 7.68 years: Finny Kuruvilla (2012), I-hung Shih (2024). Management tenure is more important for actively managed funds than passive index funds.
The fund has 2 primary benchmarks: Bloomberg US 3000 Equal Weight TR USD index with a weighting of 100% and S&P Biotechnology Select Industry TR USD index with a weighting of 100%. Eventide Healthcare & Life Sciences N has 90 securities in its portfolio. The top 10 holdings constitute 33.4% of the fund’s assets. The fund meets the SEC requirement of being classified as a diversified fund. The fund is considered to have an ESG focus with its investment selection and management.
Eventide Healthcare & Life Sciences N is part of the Equity global asset class and is within the Sector Equity fund group. Eventide Healthcare & Life Sciences N has 5.1% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 86.9%. There is 5.1% allocated to foreign stock, and 1.9% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Eventide Healthcare & Life Sciences N has 6.1% of the portfolio in cash.
Assets Under Management
The fund has $82 million in total assets, which is below the $869 million average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
ETNHX Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Eventide Healthcare & Life Sciences N expense ratio is high compared to funds in the Health category. Eventide Healthcare & Life Sciences N has an expense ratio of 1.51%, which is 25% higher than its category average, making the fund expense ratio grade a D. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Eventide Healthcare & Life Sciences N has a portfolio turnover rate of 41%, indicating that holds its assets around 0.0 years. By way of comparison, the average portfolio turnover is 61% for the Health category.
Recently, in the month of June 2026, Eventide Healthcare & Life Sciences N returned 11.8%, which earned it a grade of A, as the Health category had an average return of 8.4%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all funds in that category.
Eventide Healthcare & Life Sciences N has a trailing yield of 0.00%, which is below the 0.39% category average. The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Eventide Healthcare & Life Sciences N Grades
Year to date, the fund has returned 12.1%, 4.6 percentage points better than the category, which translates into a grade of A. The fund has returned 71.4% over the past year (grade of A), 15.5% over the past three years (grade of A) and 6.6% per year over the past five years (grade of B) and 14.6% per year over the past 10 years (grade of A).
For more mutual fund grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Eventide Healthcare & Life Sciences N, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
ETNHX Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| ETNHX Return (NAV) | 11.8% | 17.7% | 71.4% | 15.5% | 6.6% | 14.6% |
| ETNHX Grade | A | A | A | A | B | A |
| +/- Category | 3.4% | 5.8% | 37.8% | 4.6% | 1.4% | 4.6% |
| Health Avg | 8.4% | 11.9% | 33.6% | 11.0% | 5.2% | 10.0% |
| ETNHX Tax Cost Ratio | na | na | 0.0% | 0.0% | 0.6% | 0.7% |
ETNHX Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| ETNHX Return (NAV) | 12.1% | 56.4% | -10.3% | 10.8% | -19.8% | -16.8% | 36.8% | 58.4% | -0.4% | 45.6% | -16.2% |
| ETNHX Grade | A | A | F | A | F | F | A | A | C | A | F |
| +/- Category | 4.6% | 35.8% | -12.8% | 5.2% | -10.4% | -25.5% | 12.3% | 30.0% | -0.7% | 22.2% | -5.3% |
| Health Avg | 7.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 24.5% |
| Total Risk Index: | 2.02 - High |
| Category Risk Index: | 1.54 - High |
| Category Risk Grade: | F (102% Rank) |
| Beta: | 1.01 |
| R-Squared: | 27% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Small-Cap Growth |
| Bond Investment Style: | na |
| Yield: | 0.0% |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $1788 Mil |
| Fund Total Assets: | $ 82 Mil |
| Share Class Type: | N |
| Portfolio Turnover: | 41% |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 13.5 years | |||
| Average Tenure: 7.7 years | |||
| Managers (Year): Kuruvilla Finny (2012), Shih I-hung (2024) | |||
Portfolio Composition (as of 3/31/26)
| # of Holdings: | 90 |
| % in Top 10 Holdings: | 33.4% |
| Fund is Non-Diversified: | No |
| % in Foreign Issues: | 5.1% |
Portfolio Allocation |
|
| Domestic Stock: | 86.9% |
| Foreign Stock: | 5.1% |
| Preferred Stock: | 1.9% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 6.1% |
Purchase Information
| Fund Family: | Eventide Funds |
| Phone Number: | 877-771-3836 |
| Website: |
| Status: | Open |
| Inception Date: | December 27, 2012 |
| Min. Initial Purchase: | $1,000 |
| Min. Initial IRA Purchase: | $1,000 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.20% |
Expenses and Fees | |
| Expense Ratio (%): | 1.51% ( Rating : High ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Eventide Healthcare & Life Sciences I |
| Min. Subsequent Purchase: | $ 50 |
| Min. Subsequent IRA Purchase: | $ 50 |
